Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells $112,100.00 in Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Adam Crystal sold 5,000 shares of the business’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $22.42, for a total transaction of $112,100.00. Following the transaction, the insider owned 115,743 shares in the company, valued at approximately $2,594,958.06. The trade was a 4.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Adam Crystal also recently made the following trade(s):

• On Thursday, October 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $24.47, for a total value of $660,690.00.

Tango Therapeutics Price Performance

Shares of NASDAQ TNGX opened at $21.50 on Friday. The company’s fifty day simple moving average is $23.34 and its 200 day simple moving average is $22.48. Tango Therapeutics, Inc. has a 12-month low of $7.37 and a 12-month high of $34.39.

Tango Therapeutics (NASDAQ:TNGX) last announced its earnings results on Tuesday, August 11th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05). As a group, sell-side analysts forecast that Tango Therapeutics, Inc. will post -1.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Fisher Asset Management LLC raised its stake in shares of Tango Therapeutics by 84.8% during the 3rd quarter. Fisher Asset Management LLC now owns 1,068,505 shares of the company’s stock valued at $26,659,000 after purchasing an additional 490,347 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in Tango Therapeutics by 4.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 13,734 shares of the company’s stock valued at $336,000 after acquiring an additional 534 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in Tango Therapeutics in the third quarter valued at $215,000. Profund Advisors LLC grew its holdings in shares of Tango Therapeutics by 48.8% in the third quarter. Profund Advisors LLC now owns 62,319 shares of the company’s stock valued at $1,555,000 after purchasing an additional 20,430 shares during the period. Finally, Vise Technologies Inc. purchased a new stake in shares of Tango Therapeutics during the third quarter worth approximately $319,000. Institutional investors and hedge funds own 78.99% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on TNGX shares. Guggenheim upped their price target on Tango Therapeutics from $32.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Stifel Nicolaus set a $55.00 price target on Tango Therapeutics in a report on Friday, October 23rd. Wall Street Zen lowered shares of Tango Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. HC Wainwright reaffirmed a “buy” rating and set a $68.00 price target on shares of Tango Therapeutics in a report on Thursday, October 29th. Finally, Mizuho boosted their price objective on shares of Tango Therapeutics from $36.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, July 17th. Thirteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $44.62.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing medicines for cancer. The company uses functional genomics and genetic screening to identify vulnerabilities in tumor cells, including dependencies created by tumor-suppressor gene loss, and to develop targeted therapies designed to selectively attack cancer cells.

Tango’s pipeline includes small-molecule programs for genetically defined solid tumors. Its lead program, TNG462, is an MTA-cooperative PRMT5 inhibitor being developed for cancers with MTAP gene deletions.